Biogen (NASDAQ: BIIB) reported Q1 EPS of $3.40, $0.12 better than the analyst estimate of $3.28. Revenue for the quarter came in at $2.46 billion versus the consensus estimate of $2.34 billion.

GUIDANCE:

Biogen sees FY2023 EPS of $15.00-$16.00, versus the consensus of $15.48.

• Total revenue Mid-single digit percentage decline versus reported full year 2022

For earnings history and earnings-related data on Biogen (BIIB) click here.